Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668674 | 1.00 | BTK (0.51) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL1865230 | 1.00 | BTK (0.51) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL3903151 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL1155174 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL16295450 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL3901032 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL19156343 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL3906349 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL6510047 | 0.88 | BTK (0.55) | BTKNR1H2KMT2AL3MBTL1CTSK | |
| SCHEMBL23331597 | 0.86 | BTK (0.49) | BTKKMT2AL3MBTL1CTSKCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624029-B2 | JAK inhibitor compounds, method for synthesizing same and use thereof | Galderma Holding SA (CH) | 2026-05-12 | — | — | US | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| CN-117940437-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116917285-A | Novel JAK inhibitor compounds, methods of synthesis and uses thereof | 高德美控股有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20130296292-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| US-20130296290-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-11-07 | — | — | US | disclosed |
| WO-2013149121-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | CUBIST PHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| EP-2606041-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024363-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2008119720-A1 | 1-(1-CYCLOBUTYL-4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| EP-0644872-B1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA GEIGY AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| US-5516806-A | ANTITUMOR | CIBA-GEIGY CORPORATION (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0644872-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS. | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| WO-1994024093-A1 | ORNITHINE DECARBOXYLASE INHIBITING CYCLIC AMINOOXY COMPOUNDS | CIBA-GEIGY AG (CH) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | BTK 783/4885NR1H2 3017/4885KMT2A 1676/4885 |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | BTK 676/4885NR1H2 1926/4885KMT2A 2521/4885 |
| US-20130296290-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | BTK 885/4885NR1H2 3323/4885KMT2A 3510/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | BTK 684/4885NR1H2 1934/4885KMT2A 2659/4885 |
| US-12624029-B2 | JAK inhibitor compounds, method for synthesizing same and use thereof | JAK2, JAK1, JAK3 | BTK 116/4885NR1H2 68/4885KMT2A 1875/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | BTK 2261/4885NR1H2 1268/4885KMT2A 909/4885 |
| US-20130296292-A1 | 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS | BTD, BLVRB, PEPD | BTK 885/4885NR1H2 3323/4885KMT2A 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.